IDX blocks the production of S1P, with laboratory studies showing that immune cells subsequently turn a ‘COLD’ tumour into a ‘HOT’ one. In our considered opinion, this makes Veyonda the only technology currently being tested that deals directly with S1P levels as a primary cause of tumour ‘COLDNESS’.
From a business perspective, a provider either has to offer the same service or product as everyone else - but does it better - or, come up with something that is a point of difference (as the above extract suggests) to its rivals. I continue to invested in NOX because in my opinion, it does both.
NOX Price at posting:
46.0¢ Sentiment: Buy Disclosure: Held
